Douglas Wolf

P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P 1 and S1P ...

Remo Panaccione ;

Douglas Wolf ;

AnnKatrin Petersen ;

Marc Pondel ;

Bruce E. Sands , MD, MS;

Michael Silver ;

Edward V. Loftus Jr., MD;

Jean-Frederic Colombel ;

Andreas Sturm ;

Geert D'Haens ;

12/15/2021

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study

BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...

Stephen B. Hanauer , MD;

Michael Silver ;

Brian G. Feagan ;

Raymond Cross , MD;

David Hudesman , MD;

Douglas Wolf ;

Millie D. Long , MD, MPH;

Subrata Ghosh ;

AnnKatrin Petersen ;

Marc Pondel ;

12/15/2021

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P 1 and S1P ...

Raymond Cross , MD;

Jonathan Calkwood ;

Ashwini Pai ;

Millie D. Long , MD, MPH;

Ayanbola Elegbe ;

James Sheffield ;

Douglas Wolf ;

Adil Javed ;

AnnKatrin Petersen ;

Marc Pondel ;

Lorna Charles ;

Harris A. Ahmad ;

12/15/2021

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

October 29 ⁠–⁠ November 2

November 1 ⁠–⁠ November 2

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

See Full Calendar

Douglas Wolf

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products